HUGroup Holdings (MRCHF) Stock Forecast & Price Target
MRCHF Analyst Ratings
There are no analyst ratings in the last 3 months.
MRCHF Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Tomoko Yoshihara | UBS | $27.73→$24.24 | buy | -1.05%Downside | Reiterated | 05/28/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Tomoko Yoshihara | 05/28/26 | $27.73→$24.24 | buy | -1.05%Downside | Reiterated | UBS |
Best Analysts Covering HUGroup Holdings
Copying Google Medical - Diagnostics and Research's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +10.10% per trade.
Copying Google Medical - Diagnostics and Research's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +17.45% per trade.
Copying Google Medical - Diagnostics and Research's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +17.45% per trade.
MRCHF Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 1 | 0 | 0 | 0 |
In the current month, MRCHF has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MRCHF average Analyst price target in the past 3 months is ―.
MRCHF Financial Forecast
MRCHF Earnings Forecast
Next quarter’s earnings estimate for MRCHF is $0.15 with a range of $0.15 to $0.15. The previous quarter’s EPS was $0.18. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
MRCHF Sales Forecast
Next quarter’s sales forecast for MRCHF is $404.92M with a range of $404.92M to $404.92M. The previous quarter’s sales results were $397.24M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.